Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 2 results

ea0081p388 | Endocrine-Related Cancer | ECE2022

Endocrine-metabolic disorders in patients with gastroenteropancreatic and lung neuroendocrine tumors

Zamponi Virginia , Mazzilli Rossella , Russo Flaminia , Mikovic Nevena , Rinzivillo Maria , Magi Ludovica , Trabalza Marinucci Beatrice , Siciliani Alessandra , Panzuto Francesco , Faggiano Antongiulio

Background: Neuroendocrine tumors (NETs) are characterized by long survival and slow progression. In the clinical practice adifferent types of endocrine-metabolic disorders can occur. Such disorders are either comorbidities related to the neoplasm or side effects of specific oncological treatments. The aim of this study is to evaluate type and prevalence of the endocrine-metabolic disorders in patients with gastroenteropancreatic (GEP) and lung NETs.Mate...
0 shares

ea0098t5 | Trials In Progress | NANETS2023

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Capdevila Jaume , Fazio Nicola , Alvarez Rosa , Ansquer Catherine , Baldari Sergio , Baudin Eric , Benavent Marta , Benini Lavinia , Beron Amandine , Berruti Alfredo , Cingarlini Sara , del Olmo-Garcia Maribel , Deshayes Emmanuel , Garcia-Alvarez Alejandro , Garcia-Carbonero Rocio , Haissaguerre Magalie , Hernando Jorge , Anido Herranz Urbano , Jimenez-Fonseca Paula , Lepage Come , Llana Belen , Molina-Cerrillo Javier , Panzuto Francesco , Pubul Virginia , Sansovini Maddalena , Tafuto Salvatore , Taieb David , Teule Alex , Versari Annibale , Villacampa Guillermo , Walter Thomas

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more